Sqstm1 — Sequestosome 1 (P62) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
SQSTM1 (Sequestosome-1), also known as p62, is a multifunctional scaffolding protein encoded by the SQSTM1 gene on chromosome 5q35.3[1]. It serves as a critical hub in cellular homeostasis, coordinating protein degradation pathways including autophagy and the ubiquitin-proteasome system. SQSTM1 mutations are causally linked to [Paget disease of bone[/diseases/[pagod[/diseases/[pagod[/diseases/[pagod--TEMP--/diseases)--FIX-- (PDB) and are significant genetic risk factors for [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- (ALS), [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (FTD), and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- (PD)[2].
p62/SQSTM1 is a 440-amino acid protein with multiple functional domains:
- PB1 domain (Phox and Bem1p): N-terminal protein-protein interaction domain
- ZZ zinc finger domain: Binds to RIP1 and other signaling proteins
- TRAF6-binding (TB) domain: Mediates interactions with TRAF6 for NF-κB signaling
- p38 kinase interaction motif: Binds p38 MAP kinases
- LC3-interacting region (LIR): Critical for autophagy receptor function[3]
- UBA domain (Ubiquitin-Associated): Binds polyubiquitin chains at the C-terminus
p62 functions as a selective autophagy receptor:
- Cargo recognition: Binds to ubiquitinated protein aggregates through its UBA domain
- Autophagosome recruitment: LIR domain interacts with LC3 on autophagosomes
- Aggregate clearance: Facilitates removal of misfolded proteins and damaged organelles
- Keap1-Nrf2 pathway: Sequesters Keap1, allowing Nrf2 transcription factor activation and antioxidant response[4]
p62 participates in protein quality control:
- Binds ubiquitinated substrates for proteasomal degradation
- Links ubiquitination signaling to autophagy
- Regulates proteasome assembly and function
p62 is a key signaling scaffold:
- NF-κB pathway: Through TRAF6 binding, activates pro-survival NF-κB signaling[5]
- mTORC1 signaling: Acts as a nutrient sensor, regulating mTORC1 activity in response to amino acid levels
- ERK signaling: Interacts with MAP kinase pathways
- Apoptosis regulation: Modulates caspase activation and cell death
p62 is ubiquitously expressed with particular importance in:
- Neurons (especially dopaminergic neurons)
- Osteoclasts (bone-resorbing cells)
- Muscle fibers
- Immune cells (macrophages, lymphocytes)
- Liver and kidney
SQSTM1 mutations are a significant cause of ALS and FTD:
- P392L mutation: Most common pathogenic variant, associated with typical ALS and FTD-ALS[2]
- D335G mutation: Linked to ALS with or without FTD
- Prevalence: ~1-3% of ALS cases carry SQSTM1 mutations
- Phenotype: Often presents with bulbar-onset ALS, with cognitive involvement in some patients
Molecular mechanisms:
- Impaired autophagy leads to accumulation of toxic protein aggregates
- Disrupted p62-TRAF6-NF-κB signaling affects neuroinflammation
- Altered stress response in motor neurons
SQSTM1 mutations cause FTD with or without ALS:
- p62 inclusions are a hallmark of FTD-TDP pathology
- Mutations impair selective autophagy
- Shared pathophysiology with ALS (TDP-43 proteinopathy)
SQSTM1 is genetically associated with PD risk:
- Genetic association: GWAS have identified SQSTM1 variants associated with PD risk
- Pathology: p62-positive inclusions found in PD brains (Lewy bodies)
- Mechanism: Impaired autophagy-lysosomal pathway in dopaminergic neurons
SQSTM1 mutations were first identified in PDB:
- P392L: Most common pathogenic mutation (~20-50% of familial PDB)
- Other mutations: M404V, G425R, A381V
- Mechanism: Dysregulated osteoclast activity due to altered NF-κB signaling[6]
- Huntington's disease: p62 aggregates in HD brains
- Alzheimer's disease: p62 in neurofibrillary tangles and amyloid plaques
- Multiple system atrophy: p62 in glial cytoplasmic inclusions
- AAV-mediated p62 delivery: Gene therapy to restore autophagy in neurons
- ASO therapy: Target SQSTM1 expression modulation
- Autophagy inducers: Rapamycin, trehalose to enhance autophagy flux
- NF-κB inhibitors: Modulate neuroinflammation
- Keap1-Nrf2 activators: Boost antioxidant response (e.g., sulforaphane)
- Enhance autophagy to clear protein aggregates
- Stabilize p62-UBA domain interactions
- Promote lysosomal function
- Shin J. Unveiling the functions of p62/SQSTM1 in the brain. Exp Mol Med. 2023;55(6):1195-1206. DOI:10.1038/s12276-023-01011-2<sup>[1]
- Rubino E, et al. SQSTM1 mutations in ALS and FTD: pathogenetic link to p62. Neurology. 2018;90(15):e1334-e1341. DOI:10.1212/WNL.0000000000005301<sup>[2]
- Ichimura Y, et al. Structural basis for selective autophagy of p62/SQSTM1. J Mol Biol. 2014;426(13):2535-2546. DOI:10.1016/j.jmb.2014.01.012<sup>[3]
- Komatsu M, et al. The selective autophagy substrate p62 activates the stress-responsive transcription factor Nrf2 through Keap1 degradation. Nat Cell Biol. 2010;12(3):213-223. DOI:10.1038/ncb2021<sup>[4]
- Duran A, et al. p62 is a key regulator of innate immunity in the TNF pathway. Cell. 2008;133(5):891-906. DOI:10.1016/j.cell.2008.04.015<sup>[5]
- Hocking LJ, et al. Domain-specific mutations in SQSTM1 cause Paget disease of bone. Nat Genet. 2002;32(1):88-92. DOI:10.1038/ng963<sup>[6]
- [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--
- [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--
- [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [Autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--
- [Ubiquitin-Proteasome System[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system--TEMP--/entities)--FIX--
- [p62 Protein[/proteins/[p62-protein[/proteins/[p62-protein[/proteins/[p62-protein--TEMP--/proteins)--FIX--
- [TDP-43[/proteins/[tdp-43[/proteins/[tdp-43[/proteins/[tdp-43--TEMP--/proteins)--FIX--
- [Keap1-Nrf2 Pathway[/mechanisms/[keap1-nrf2-pathway[/mechanisms/[keap1-nrf2-pathway[/mechanisms/[keap1-nrf2-pathway--TEMP--/mechanisms)--FIX--
Sqstm1 — Sequestosome 1 (P62) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sqstm1 — Sequestosome 1 (P62) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.